Challenges and Considerations For Clinical Development of Targeted Therapies in Acute Myeloid Leukemia, Upcoming Webinar Hosted by Xtalks

Share Article

Targeted therapies are the focus of many anticancer drugs in development today. From a clinical development standpoint, these exciting, novel approaches (immunotherapies, monoclonal antibodies, gene therapies, etc.) bring new complexities, challenges and considerations. In this interactive webinar, Medpace experts will discuss key clinical, operational and laboratory considerations, lessons learned and best practices for accelerating the global development of safe and effective targeted therapeutics, using acute myeloid leukemia (AML) to highlight the complexities.

Xtalks Life Science Webinars

Within the last several years, there has been a marked shift in the treatment of AML from an intense/upfront chemotherapeutic approach for all patients to a more defined and targeted therapy based on specific disease features.

Advances in the treatment of acute myeloid leukemia (AML) have resulted in large part from improved molecular techniques, such as next-generation sequencing (NGS) which allows for the identification of specific molecular mutations within leukemic cells. The presence of such mutations not only provides prognostic information but may also function as the target(s) for anti-AML therapy.

On Wednesday, October 23, 2019 at 11am EDT (4pm BST/UK), join experts from Medpace in a live webinar where they will take participants through a case study on AML, a heterogeneous disease characterized by a spectrum of clinical and molecular features. Within the last several years, there has been a marked shift in the treatment of AML from an intense/upfront chemotherapeutic approach for all patients to a more defined and targeted therapy based on specific disease features.

Topics will include:

  •     Clinical: How mutation analyses in AML allow for prognostic classification and a targeted therapy approach
  •     Operational: Considerations for the execution of AML clinical trials in a competitive landscape
  •     Laboratory/Assays: How new standards for NGS-based treatment decisions and monitoring have to be further defined

Participants will hear from the following Medpace speakers:

  •     Patricia L. Kropf, MD, Medical Director
  •     Jeffrey Vassallo, PhD, Associate Director, Clinical Trial Management
  •     El Mustapha Bahassi, PhD, Associate Director, Clinical Laboratory

For more information or to register for this event, visit Challenges and Considerations For Clinical Development of Targeted Therapies in Acute Myeloid Leukemia.

ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
+1 (416) 977-6555 x400
Email >
Visit website